

CLAIMS

1. The use of a furin inhibitor in the manufacture of a medicament for reducing scarring during the healing of wounds or reducing fibrosis in the treatment of fibrotic conditions wherein the medicament is topically applied to the site of a wound or fibrotic disorder.
2. The use according to claim 1 wherein the inhibitor is a serine protease inhibitor.
3. The use according to any preceding claim wherein the inhibitor is lipid soluble.
4. The use according to claim 2 wherein the inhibitor is a peptidyl chloroalkylketone having a peptide moiety which mimics at least one convertase enzyme cleavage site.
5. The use according to claim 2 wherein the inhibitor is decanoyl-RVKR-cmk.
6. The use according to claim 1 or claim 2 wherein the inhibitor is water soluble.
7. The use according to claim 6 wherein the inhibitor is hexa-arginine.
8. The use according to any preceding claim for treating wounds to inhibit or prevent scar formation.
9. The use according to claim 8 for inhibiting or preventing scarring of the eye, nervous tissue or intestines.
10. The use according to claim 8 for inhibiting or preventing dermal scarring.

11. The use according to claim 8 for inhibiting or preventing scarring following a burn.
12. The use according to any one of claims 1 to 7 for reducing fibrosis in the treatment of fibrotic conditions.
13. The use according to claim 12 wherein the fibrotic condition is a fibrotic disorder selected from glomerulonephritis, cirrhosis of the liver, fibrocytic disease, adhesions or restenosis.